stockrow
Friday 6 November 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
76.08
11.28
+17.41%
Follow CGON
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 3 | — |
+8 more TTM periods Free account |
| (28.29%) | (26.41%) | (20.79%) | (21.67%) | ||
| (26.73%) | (25.11%) | (20.04%) | (20.82%) | ||
ROIC |
(1,740.24%) | (4,111.64%) | (724.76%) | (886.69%) | |
Return on Tangible Assets |
(24.32%) | (22.06%) | (17.26%) | (21.63%) | |
Average Days of Receivables |
0.00 | 24.44 | 90.84 | 55.85 | |
Free Cash Flow per Share |
(2.13) | (2.03) | (1.90) | (1.71) | |
Free Cash Flow |
(189.17) | (179.34) | (160.43) | (132.48) | |
Capital Expenditures |
(1.89) | (0.88) | (0.42) | (0.13) | |
| Other line items | |||||
Cash ROIC |
(9.56%) | (8.70%) | (7.39%) | (8.85%) | |
Accounts Receivable Turnover |
0.00 | 12.72 | 6.32 | 6.12 | |
Accounts Payable Turnover |
0.00 | 1.16 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
0.00 | 402.75 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 31.74 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,717.60% | 2,508.51% | 2,594.26% | 2,594.33% | |
Selling, General and Administrative Expense of Revenue |
1,471.16% | 1,462.48% | 1,552.16% | 1,635.36% | |
Share Based Compensation of Revenue |
591.16% | 567.21% | 546.54% | 593.33% | |
Operating CF/Net income |
0.79 | 0.80 | 0.86 | 0.82 | |
Depreciation/Fixed assets |
0.00 | 0.13 | 0.21 | 0.03 | |
Capex/Depreciation |
0.00 | (0.45) | (0.13) | (0.31) | |
Revenue per Share |
0.07 | 0.07 | 0.06 | 0.06 | |
Operating CF per Share |
(2.11) | (2.02) | (1.89) | (1.71) | |
Capex per Share |
(0.02) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.31 | 0.14 | 0.08 | 0.03 |
Columns are period end dates · fundamentals updated 6 Nov 2026